Bifemelane

Bifemelane
Systematic (IUPAC) name
N-methyl-4-[2-(phenylmethyl)phenoxy]butan-1-amine
Clinical data
AHFS/Drugs.com International Drug Names
Identifiers
CAS Number 90293-01-9 YesY
ATC code N06AX08 (WHO)
PubChem CID 2377
ChemSpider 2286 YesY
UNII Z4501GN13G YesY
ChEMBL CHEMBL1192517 N
Synonyms MCl-2016
Chemical data
Formula C18H23NO
Molar mass 269.381 g/mol
 NYesY (what is this?)  (verify)

Bifemelane (INN) (Alnert, Celeport), or bifemelane hydrochloride (JAN), also known as 4-(O-benzylphenoxy)-N-methylbutylamine, is an antidepressant and cerebral activator that is widely used in the treatment of cerebral infarction patients with depressive symptoms in Japan, and in the treatment of senile dementia as well.[1][2] It also appears to be useful in the treatment of glaucoma.[3] Bifemelane acts as a monoamine oxidase inhibitor (MAOI) of both isoenzymes, with competitive (reversible) inhibition of MAO-A (Ki = 4.20 μM) (making it a reversible inhibitor of MAO-A (RIMA)) and non-competitive (irreversible) inhibition of MAO-B (Ki = 46.0 μM),[4][5][6] and also acts (weakly) as a norepinephrine reuptake inhibitor.[7] The drug has nootropic, neuroprotective, and antidepressant-like effects in animal models, and appears to enhance the cholinergic system in the brain.[8][9][10]

See also

References

  1. ↑ Koide S, Onishi H, Hashimoto H, Kai T, Katayama M, Yamagami S (1995). "Effects of bifemelane hydrochloride on plasma neuropeptide Y, 3-methoxy-4-hydroxyphenylethylene glycol and 5-hydroxy-indole acetic acid concentrations in patients with cerebral infarction". Drugs Exp Clin Res 21 (5): 175–80. PMID 8846747.
  2. ↑ David J. Triggle (1996). Dictionary of Pharmacological Agents. Boca Raton: Chapman & Hall/CRC. p. 265. ISBN 0-412-46630-9.
  3. ↑ Shigemitsu, T; Majima, Y (1996). "Use of bifemelane hydrochloride in improving and maintaining the visual field of patients with glaucoma". Clinical therapeutics 18 (1): 106–13. doi:10.1016/S0149-2918(96)80183-4. PMID 8851457.
  4. ↑ Naoi, Makoto; Nomura, Yoshio; Ishiki, Ryoji; Suzuki, Hiroko; Nagatsu, Toshiharu (1988). "4-(O-Benzylphenoxy)-N-Methylbutylamine (Bifemelane) and Other 4-(O-Benzylphenoxy)-N-Methylalkylamines as New Inhibitors of Type A and B Monoamine Oxidase". Journal of Neurochemistry 50 (1): 243–247. doi:10.1111/j.1471-4159.1988.tb13256.x. ISSN 0022-3042.
  5. ↑ Kovel'man, I. R.; Tochilkin, A. I.; Gorkin, V. Z. (1991). "Structure and action of reversible monoamine oxidase inhibitors (review)". Pharmaceutical Chemistry Journal 25 (8): 505–520. doi:10.1007/BF00777412. ISSN 0091-150X.
  6. ↑ Jae Y. Choe (4 March 2011). Drug Actions and Interactions. McGraw Hill Professional. p. 307. ISBN 978-0-07-176945-7.
  7. ↑ Dostert, P. (1994). "Can our knowledge of monoamine oxidase (MAO) help in the design of better MAO inhibitors?": 269–279. doi:10.1007/978-3-7091-9324-2_35. For example, bifemelane [4-(O-benzylphenoxy)-N-methylbutylamine) is one of the few molecules in which both activities, reversible inhibition of MAO-A (Naoi et al., 1988) and inhibition of noradrenaline uptake (Egawa et al., 1983), although weak (IC50 = 10-6-10-7 M), coexist.
  8. ↑ Kondo, Y; Ogawa, N; Asanuma, M; Matsuura, K; Nishibayashi, K; Iwata, E (1996). "Preventive effects of bifemelane hydrochloride on decreased levels of muscarinic acetylcholine receptor and its mRNA in a rat model of chronic cerebral hypoperfusion". Neuroscience research 24 (4): 409–14. doi:10.1016/0168-0102(95)01017-3. PMID 8861111.
  9. ↑ Egashira, T; Takayama, F; Yamanaka, Y (1996). "Effects of bifemelane on muscarinic receptors and choline acetyltransferase in the brains of aged rats following chronic cerebral hypoperfusion induced by permanent occlusion of bilateral carotid arteries". Japanese journal of pharmacology 72 (1): 57–65. doi:10.1254/jjp.72.57. PMID 8902600.
  10. ↑ Moryl E, Danysz W, Quack G (June 1993). "Potential antidepressive properties of amantadine, memantine and bifemelane". Pharmacology & Toxicology 72 (6): 394–7. doi:10.1111/j.1600-0773.1993.tb01351.x. PMID 8361950.


This article is issued from Wikipedia - version of the Saturday, April 02, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.